| Project/Area Number |
23591858
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
KIMURA Fumio 千葉大学, 医学(系)研究科(研究院), 特任教授 (70334208)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAZAKI Masaru 千葉大学, 医学研究院, 教授 (70166156)
SHIMIZU Hiroaki 千葉大学, 医学研究院, 准教授 (80272318)
YOSHIDOME Hiroyuki 千葉大学, 医学研究院, 講師 (10312935)
TAKAYASHIKI Takashi 千葉大学, 医学部付属病院, 助教 (30456024)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | パターン認識受容体 / プリン受容体 / 重症感染症 / 臓器不全 |
|---|
| Research Abstract |
Background: The role of purinergic receptors in pathogenesis of postoperative critical illness following major surgery was prospectively investigated. Methods: Expression levels of P2X7, A2A, T-bet, and GATA-3 mRNA in peripheral blood mononuclear cells were assayed by reverse transcription-polymerase chain reaction perioperatively in 49 consecutive patients who underwent major hepatobiliary pancreatic surgery. Results: P2X7 mRNA expression and P2X7/A2A ratio were significantly lower in unfavorable group (p < 0.05) in preoperative or early postoperative period. Postoperative T-bet/GATA-3 ratio was significantly lower in unfavorable group (p < 0.05). T-bet/GATA-3 ratio correlated significantly with P2X7 mRNA expression and P2X7/A2A ratio on POD 0 and 1 (p < 0.01). P2X7 mRNA expression on POD 0 negatively correlated with severity of complications (p < 0.05). Conclusions: These results suggest that P2X7 and A2A may play a pivotal role in pathogenesis of postoperative critical illness.
|
